Tag: HIV-1

Findings A UCLA research team has shown that using a truncated form of the CD4 molecule as part of a gene therapy to combat HIV yielded superior and longer-lasting results in mouse models than previous similar therapies using the CD4 molecule. This new approach to CAR T gene therapy — a type of immunotherapy that

(HealthDay)—For patients with HIV-1 suppression, long-acting cabotegravir plus rilpivirine is noninferior to oral therapy with dolutegravir-abacavir-lamivudine and standard oral therapy, according to two studies published online March 4 in the New England Journal of Medicine. Chloe Orkin, M.D., from the Queen Mary University of London, and colleagues conducted a phase 3 randomized trial involving adults

The cover for issue 54 of Oncotarget features Figure 2, “Comparative proteomic profiling of the peptides/proteins identified from 293T, IL16lamp2b and mExo-Tat samples,” by Lu, et al. The HIV-1 Tat protein is a potent activator of viral transcription. The researcher’s previous work has demonstrated that exosomal formulations of Tat can reverse HIV-1 latency in primary

A mutation that causes a type of muscular dystrophy that affects the limbs protects against HIV-1 infection, according to a study published August 29 in the open-access journal PLOS Pathogens by Sara Rodríguez-Mora, Mayte Coiras and José Alcamí of the Instituto de Salud Carlos III in Madrid, Spain, and colleagues. As the authors noted, this